News

Merck jumps after CHMP backs Keytruda plus Padcev for certain bladder cancer patients, a combo with the potential to expand treatment options.

More CEOs use AI to make business decisions than you might think.

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

The pharma giant is taking steps to expand its portfolio.

iShares Select Dividend ETF (NASDAQ:DVY) is one of the older income-focused funds on the market. The question for owners is simple: can the income stream hold up? DVY pays variable quarterly distributions sourced from dividends of roughly 100 U.S. companies screened for payout history and yield, and it currently throws off a trailing yield of ... Why Retirees Keep Buying This Dividend ETF After 22 Years of Payments

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

Go beyond the broad index and find which segment of healthcare best suits your portfolio needs now.

Pfizer (NYSE:PFE) has entered a new alliance with Sarah Cannon Research Institute to accelerate oncology clinical trials and broaden patient access. The company has also granted Rigel Pharmaceuticals exclusive rights to commercialize VEPPANU, an FDA approved PROTAC based breast cancer therapy. These agreements reflect fresh moves in Pfizer's oncology R&D and commercialization approach that have not been covered in earlier updates. Pfizer's stock closed at $25.9, with the share price up 2.3%...

Pfizer currently trades at $25.89 per share and has shown little upside over the past six months, posting a middling return of 2.7%. The stock also fell short of the S&P 500’s 10.8% gain during that period.

The Invesco S&P 500 High Dividend Low Volatility ETF (NYSEARCA:SPHD) sends income to shareholders every month, with distributions rising roughly 23% in 2025 and 2026 monthly payouts climbing to around $0.208 per share, with a current 30-day SEC yield of 4.5%. The question is whether that income rests on a durable foundation or whether recent ... SPHD Pays Monthly Income Without Fail Since 2012; Here’s What Could Break the Streak

As Kevin Warsh steps up to lead the Federal Reserve, the case for interest-rate cuts is disappearing. Plus, investment newsletter commentary on AI”s circular ecosystem, emerging markets, and SpaceX.

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.

Scott Melker discusses the history and structure of the Federal Reserve and presents bitcoin as a decentralized alternative. “The Daily Wolf with Scott Melker” airs on Yahoo Finance every day at 12:00 p.m. Tune in for your daily dose of all things crypto.Make sure to also check out Yahoo Finance's new crypto hub to find the latest crypto-related news.

Merck shares rose after partner Kelun-Biotech reported positive late-stage trial results for a Keytruda combination treatment in lung cancer.

JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued US Stocks According to Hedge Funds. On May 13, Pfizer Inc. (NYSE:PFE) announced receiving marketing authorization from the European Commission to expand the use of HYMPAVZI (marstacimab) for hemophilia A and B patients aged 12+ who have developed inhibitors. ​Management noted that roughly 20% of hemophilia […]

Pfizer (PFE) is back in focus after two R&D milestones, a broader European indication for hemophilia drug HYMPAVZI and positive Phase 2 data for its 25 valent pneumococcal vaccine in infants, sparked fresh interest in the stock. See our latest analysis for Pfizer. Despite the HYMPAVZI approval and vaccine pipeline updates, the share price is still around US$25.79, with a 30 day share price return down 6.29% but a 1 year total shareholder return of 19.76%. This suggests recent momentum has...

The market appears to be short-sighted.

Earlier in May 2026, Pfizer reported positive Phase 2 results for its investigational 25‑valent pneumococcal conjugate vaccine in infants, showing strong immune responses versus PREVNAR 20 and prompting the launch of a pivotal Phase 3 pediatric program. The move to a broader 25‑strain infant vaccine candidate, alongside plans for a fifth‑generation 35‑valent adult vaccine, highlights how Pfizer is aiming to extend its long-standing pneumococcal franchise through higher‑value, next‑generation...

Pfizer and its partners have granted Rigel Pharmaceuticals an exclusive license to commercialize VEPPANU (vepdegestrant), the first FDA approved oral PROTAC for advanced breast cancer. The agreement follows Phase 3 data that support clinical benefit in a difficult to treat patient group and inclusion of VEPPANU in NCCN breast cancer guidelines. The deal introduces a new commercialization pathway for VEPPANU and adds another partnership driven revenue channel for Pfizer. For investors...

New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.

PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.

(Bloomberg) -- Turns out, loading up on technology giants isn’t the only route to better returns. Value companies, too, stand a decent chance of trouncing the market — as long as several conditions are met. Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Threatens Iran With ‘Bi

Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.

The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.

With markets at elevated multiples in May 2026, low share prices can mislead investors into thinking quality is out of reach. Stocks trading below $30 with strong balance sheets offer income, deleveraging stories, or growth at valuations that build in a margin of safety. Here are five stocks trading under $30 that pair solid books ... The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

BridgeBio Pharma (NASDAQ:BBIO) received a Neutral initiation from Citi Neutral on Tuesday, reflecting a measured stance on the company’s transthyretin amyloid cardiomyopathy (ATTR-CM) franchise. The call contrasts with Citi’s simultaneous Buy initiation Buy ratings on peer biotechs Alnylam, Ascendis Pharma, BioMarin, Cytokinetics, and of Ionis Pharmaceuticals (NASDAQ:IONS), making the BBIO Neutral a cautious outlier. For ... Citi Initiates BridgeBio at Neutral: Why the Cardiomyopathy Story Isn’t

With short-term rates still elevated, tariff uncertainty churning through earnings models, and credit spreads widening at the margins, balance sheet quality has quietly become the most underrated factor in equity selection. Stocks under $30 often get dismissed as broken or speculative, but a handful of large, cash-generative businesses currently trade in that zone with the ... Rate Cuts Are Off the Table. Here Are 2 Stocks Under $30 Built Exactly for This Moment